Anti-TNFs: Originators and Biosimilars

Publisher： Karger

E-ISSN： 1421-9875|34|1-2|132-139

ISSN： 0257-2753

Source： Digestive Diseases, Vol.34, Iss.1-2, 2016-03, pp. : 132-139

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Biosimilars: Are They Bioequivalent?

By  

Digestive Diseases, Vol. 32, Iss. 1, 2014-12 ,pp. : 82-87

Karger

Access to resources Recommend Favorite

Biosimilars: Aktueller Stand der Serienreife

By Aringer M.   Dörner T.  

Zeitschrift für Rheumatologie, Vol. 72, Iss. 9, 2013-11 ,pp. : 873-877

Springer Publishing Company

Access to resources Recommend Favorite

Combining Therapeutic Drug Monitoring with Biosimilars, a Strategy to Improve the Efficacy of Biologicals for Treating Inflammatory Bowel Diseases at an Affordable Cost

By  

Digestive Diseases, Vol. 35, Iss. 1-2, 2017-02 ,pp. : 61-68

Karger

Access to resources Recommend Favorite

Does the Introduction of Biosimilars Change Our Understanding about Treatment Modalities for Inflammatory Bowel Disease?

By  

Digestive Diseases, Vol. 35, Iss. 1-2, 2017-02 ,pp. : 74-82

Karger

Access to resources Recommend Favorite

Dendrimer Based Anti-Infective and Anti-Inflammatory Drugs

By  

Recent Patents on Anti-Infective Drug Discovery, Vol. 1, Iss. 3, 2006-11 ,pp. : 333-351

Bentham Science Publishers

Access to resources Recommend Favorite